Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study
- PMID: 31504942
- DOI: 10.1093/rheumatology/kez371
Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study
Abstract
Objectives: To examine all-cause and cardiovascular disease (CVD) mortality in consecutive cohorts of patients with incident RA, compared with population comparators.
Methods: The Oslo RA register inclusion criteria were diagnosis of RA (1987 ACR criteria) and residency in Oslo. Patients with disease onset 1994-2008 and 10 matched comparators for each case were linked to the Norwegian Cause of Death Registry. Hazard ratios for all-cause and CVD mortality were calculated for 5, 10, 15 and 20 years of observation using stratified cox-regression models. Mortality trends were estimated by multivariate cox-regression.
Results: 443, 479 and 469 cases with disease incidence in the periods 94-98, 99-03 and 04-08 were matched to 4430, 4790 and 4690 comparators, respectively. For cases diagnosed between 1994 and 2003, the all-cause mortality of cases diverged significantly from comparators after 10 years of disease duration [hazard ratio (95% CI) 94-98 cohort 1.42 (1.15-1.75): 99-03 cohort 1.37 (1.08-1.73)]. CVD related mortality was significantly increased after 5 years for the 94-98 cohort [hazard ratio (95% CI) 1.86 (1.16-2.98) and after 10 years for the 99-03 cohort 1.80 (1.20-2.70)]. Increased mortality was not observed in the 04-08 cohort where cases had significantly lower 10-year all-cause and CVD mortality compared with earlier cohorts.
Conclusion: All-cause and CVD mortality were significantly increased in RA patients diagnosed from 1994 to 2003, compared with matched comparators, but not in patients diagnosed after 2004. This may indicate that modern treatment strategies have a positive impact on mortality in patients with RA.
Keywords: cardiovascular disease; epidemiology; mortality; rheumatoid arthritis; treat to target.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Comment in
-
Addressing the hardest endpoint.Rheumatology (Oxford). 2020 Mar 1;59(3):462-463. doi: 10.1093/rheumatology/kez514. Rheumatology (Oxford). 2020. PMID: 31642913 No abstract available.
Similar articles
-
Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.Ann Rheum Dis. 2017 Jun;76(6):1057-1063. doi: 10.1136/annrheumdis-2016-209562. Epub 2016 Dec 28. Ann Rheum Dis. 2017. PMID: 28031164 Free PMC article.
-
Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register.Semin Arthritis Rheum. 2017 Feb;46(4):411-417. doi: 10.1016/j.semarthrit.2016.07.011. Epub 2016 Jul 26. Semin Arthritis Rheum. 2017. PMID: 27522465
-
Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study.J Rheumatol. 2013 Dec;40(12):1958-66. doi: 10.3899/jrheum.130365. Epub 2013 Aug 15. J Rheumatol. 2013. PMID: 23950188
-
Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature.BMC Musculoskelet Disord. 2014 Apr 29;15:142. doi: 10.1186/1471-2474-15-142. BMC Musculoskelet Disord. 2014. PMID: 24779371 Free PMC article. Review.
-
Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.Dan Med J. 2018 Apr;65(4):B5454. Dan Med J. 2018. PMID: 29619932 Review.
Cited by
-
Postprandial Apolipoprotein B48 is Associated with Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis.J Clin Med. 2020 Aug 2;9(8):2483. doi: 10.3390/jcm9082483. J Clin Med. 2020. PMID: 32748862 Free PMC article.
-
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes.Ther Adv Musculoskelet Dis. 2022 Aug 16;14:1759720X221114101. doi: 10.1177/1759720X221114101. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 35991524 Free PMC article. Review.
-
Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis.Front Immunol. 2023 Aug 17;14:1211790. doi: 10.3389/fimmu.2023.1211790. eCollection 2023. Front Immunol. 2023. PMID: 37662936 Free PMC article.
-
Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases.Arthritis Res Ther. 2022 Jun 16;24(1):144. doi: 10.1186/s13075-022-02824-8. Arthritis Res Ther. 2022. PMID: 35710524 Free PMC article.
-
Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis.RMD Open. 2020 Jan;6(1):e001032. doi: 10.1136/rmdopen-2019-001032. RMD Open. 2020. PMID: 31958278 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical